Literature DB >> 8739884

Endothelins as cardiovascular peptides.

E R Levin1.   

Abstract

The normal functional state of the vasculature and the events leading to the development of significant arterial disease involve the interaction of important vasoactive substances, which play important modulating or initiating roles in the development of hypertension and arteriosclerosis. Three endothelins have now been identified, of which ET-1 is the best characterized. ET-1 is produced by epithelial, mesangial, neuronal and glial, and liver cells, and is the most potent vasoconstrictor yet found. Each endothelin is derived from a different gene on separate chromosomes, and each binds to at least 2 types of receptor. The plasma half-life of ET-1 is about 7 min, and this provides a rapid mechanism for adjusting vascular resistance or blood pressure. The actions of endothelin are mediated through several pathways of postreceptor signaling, including activation of the mitogen-activated protein kinase cascade, which give rise to its growth-stimulating properties. Secretion of ET-1 from cultured endothelial cells is stimulated by a wide range of substances, and is inhibited by some prostaglandins. Endothelin in turn stimulates secretion of nitric oxide, arginine vasopressin and atrial natriuretic peptide, and participates in the hormonal control of salt and water balance. Hypoxia and ischemia augment ET-1 secretion, as does insulin, and this could play a role in the accelerated vascular disease of diabetes. ET-1 also causes bronchoconstriction and has been implicated in the development of acute asthma, primary pulmonary hypertension and pulmonary fibrosis. Its role in hypertension is still debatable, though most of the manifestations of congestive heart failure can theoretically be explained by the actions of ET-1. Endothelin also has extensive renovascular and parenchymal effects in the kidney. It is hoped that a fuller understanding of the role of endothelins in normal or pathologic vasculature will lead to effective therapy based on antagonism or augmentation of specific functions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8739884     DOI: 10.1159/000169004

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  9 in total

1.  Endothelin receptor A and p66Shc regulate spontaneous Ca2+ oscillations in smooth muscle cells controlling renal arterial spontaneous motion.

Authors:  Oleg Palygin; Bradley S Miller; Yoshinori Nishijima; David X Zhang; Alexander Staruschenko; Andrey Sorokin
Journal:  FASEB J       Date:  2018-10-10       Impact factor: 5.191

Review 2.  Inhibition of ENaC by endothelin-1.

Authors:  Andrey Sorokin; Alexander Staruschenko
Journal:  Vitam Horm       Date:  2015-03-06       Impact factor: 3.421

Review 3.  Endothelin in heart failure.

Authors:  G Sütsch; M Barton
Journal:  Curr Hypertens Rep       Date:  1999 Feb-Mar       Impact factor: 5.369

Review 4.  Regulation of matrix proteins and impact on vascular structure.

Authors:  J Tuñón; M Ruiz-Ortega; J Egido
Journal:  Curr Hypertens Rep       Date:  2000-02       Impact factor: 5.369

Review 5.  Management of vasodilatory shock: defining the role of arginine vasopressin.

Authors:  Martin W Dunser; Volker Wenzel; Andreas J Mayr; Walter R Hasibeder
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 6.  Role of vasopressin in the management of septic shock.

Authors:  Gökhan M Mutlu; Phillip Factor
Journal:  Intensive Care Med       Date:  2004-04-21       Impact factor: 17.440

7.  Pyk2 mediates endothelin-1 signaling via p130Cas/BCAR3 cascade and regulates human glomerular mesangial cell adhesion and spreading.

Authors:  Victoriya A Rufanova; Anna Alexanian; Tetsuro Wakatsuki; Adam Lerner; Andrey Sorokin
Journal:  J Cell Physiol       Date:  2009-04       Impact factor: 6.384

8.  Plasma endothelin-1 levels in patients with biliary atresia: possible role in development of portal hypertension.

Authors:  V Chongsrisawat; P Chatchatee; R Samransamruajkit; P Vanapongtipagorn; P Chottivittayatarakorn; Y Poovorawan
Journal:  Pediatr Surg Int       Date:  2003-05-13       Impact factor: 1.827

Review 9.  Endothelial dysfunction in diabetes mellitus.

Authors:  Hadi A R Hadi; Jassim Al Suwaidi
Journal:  Vasc Health Risk Manag       Date:  2007
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.